Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. (NASDAQ: MXCT) is a cell-engineering focused company whose news flow centers on its enabling platform technologies, financial performance and strategic partnerships in next-generation cell-based therapeutics. As a commercial cell engineering company, MaxCyte regularly issues updates on its core business revenue, Strategic Platform License (SPL) program-related revenue and total cash, cash equivalents and investments, giving investors insight into how its platform is being adopted and how its financial profile is evolving.
News about MaxCyte often includes quarterly and annual financial results, preliminary earnings updates and revised guidance ranges for core revenue and SPL program-related revenue. These releases typically discuss core revenue from instruments, processing assemblies and consumables, licenses, assay services and other categories, as well as program-related revenue tied to SPL milestones and royalties. Management commentary in these announcements frequently addresses operating environment conditions, cost structure, operational restructuring and the company’s path toward profitability.
Another key category of MXCT news involves new and expanded SPL agreements with biotechnology partners. Recent press releases have highlighted SPLs with companies such as Adicet Bio and Moonlight Bio, where MaxCyte’s Flow Electroporation technology and ExPERT platform are being deployed to support scalable development and manufacturing of gene-edited T cell therapies and gamma delta T cell programs. These partnership updates help illustrate how MaxCyte’s platform is used across different cell therapy pipelines.
Corporate developments also feature in the company’s news stream. Examples include the announcement of an operational restructuring and workforce reduction plan designed to reduce costs and align resources with strategic priorities, as well as leadership transitions such as planned changes in the chief financial officer role. For investors and industry observers, following MXCT news can provide ongoing context on MaxCyte’s business performance, partner activity and strategic decisions within the cell and gene therapy ecosystem.
MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenue.
Kamau, a clinical-stage company, is developing gene correction therapies using homology-directed repair (HDR) editing. Their lead program, nula-cel, targets sickle cell disease (SCD). This partnership aims to optimize Kamau's clinical manufacturing process and expedite the development of potential cures for genetic diseases.
MaxCyte's ExPERT™ platform offers high transfection efficiency, scalability, and enhanced functionality for complex cell engineering. This marks MaxCyte's 29th clinical/commercial partnership, contributing to its pre-commercial milestone revenue stream.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering and platform technologies for cell-based therapeutics and bioprocessing applications, has announced its participation in the Virtual Craig-Hallum Capital Group Bioprocessing Conference. The event is scheduled for Thursday, September 19th at 9:30 am ET.
Company management will be presenting at the conference, providing insights into MaxCyte's innovative technologies and market position. For those unable to attend live, a replay of the event will be made available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.
This participation underscores MaxCyte's commitment to engaging with the investment community and showcasing its advancements in cell engineering and bioprocessing technologies.
MaxCyte (NASDAQ: MXCT) reported Q2 2024 financial results and updated full-year guidance. Total revenue reached $10.4 million, up 15% year-over-year. Core business revenue declined 9% to $7.6 million, while SPL Program-related revenue surged 279% to $2.9 million. The company signed five new SPL clients year-to-date, bringing the total to 28. MaxCyte affirmed its 2024 core business revenue guidance of flat to 5% growth and increased SPL Program-related revenue guidance to approximately $6 million. The company expects to end 2024 with at least $180 million in total cash, cash equivalents, and investments.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering platform technologies, will announce its Q2 2024 financial results on August 6, 2024, after the U.S. market closes. The company invites investors to join a conference call at 4:30 p.m. Eastern Time, where management will discuss these results. Interested participants should register online in advance. A live and archived webcast of the call will be available on the MaxCyte website.
MaxCyte, a leader in cell-engineering technologies, announced its participation in the William Blair 44th Annual Growth Stock Conference. The event is scheduled for June 5th at 2:40 pm CT. The session will be available live and archived on MaxCyte's investor relations website. MaxCyte focuses on advancing cell-based therapeutics and bioprocessing applications, emphasizing discovery, development, and commercialization.
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive annual licensing fees, clinical development milestones, and royalties on net sales of the licensed products. This marks MaxCyte’s 28th clinical/commercial partnership, emphasizing its role in advancing cell-based therapeutics.
The partnership aims to enhance Legend Biotech’s non-viral engineered therapeutic pipeline, leveraging MaxCyte’s expertise in scalable cell engineering and regulatory support. The ExPERT™ platform provides high transfection efficiency and seamless scalability, essential for developing innovative cell therapies. Both companies aim to transform the treatment landscape and meet expanding clinical and commercial needs.
MaxCyte, Inc. reported a total revenue of $11.3 million in the first quarter of 2024, marking a 32% increase year-over-year. Core business revenue grew by 5% to $8.2 million. The company signed four Strategic Platform License (SPL) clients year-to-date, with a total of 27 partners. Cash, cash equivalents, and investments stood at $202.5 million as of March 31, 2024. MaxCyte affirmed its 2024 revenue guidance, expecting flat to 5% growth in core business revenue and approximately $5 million in SPL Program-related revenue.
Summary not available.
Summary not available.
Summary not available.